These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28945928)

  • 21. Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors.
    Gómez-Peralta F; Abreu C; Mora-Navarro G; López-Morandeira P; Pérez-Gutierrez E; Cordero-García B; Brito-Sanfiel M
    Exp Clin Endocrinol Diabetes; 2018 May; 126(5):268-276. PubMed ID: 28704854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
    Darmon P; Raccah D
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of stepwise addition of prandial insulin to a basal-bolus regimen when basal insulin is insufficient for glycaemic control in type 2 diabetes: results of the OSIRIS study.
    Raccah D; Haak TJ; Huet D; Monnier L; Robertson D; Labard P; Soler J; Penfornis A
    Diabetes Metab; 2012 Dec; 38(6):507-14. PubMed ID: 23116646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study.
    Yenigun M; Honka M
    Int J Clin Pract; 2009 Mar; 63(3):425-32. PubMed ID: 19222627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Greater fear of hypoglycaemia with premixed insulin than with basal-bolus insulin glargine and glulisine: patient-reported outcomes from a 60-week randomised study.
    Polonsky WH; Thompson S; Wei W; Riddle MC; Chaudhari S; Jackson J; Bruno AS
    Diabetes Obes Metab; 2014 Nov; 16(11):1121-7. PubMed ID: 24919603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR; Tits J; Kinsley BT; Råstam J; Friberg HH; Ligthelm RJ
    Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
    Chamarthi B; Cincotta AH
    Postgrad Med; 2017 May; 129(4):446-455. PubMed ID: 28374645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycaemic control in type 2 diabetes mellitus patients undergoing major surgery: comparison of three subcutaneous insulin regimens.
    Mathur SK; Bansal A; Khan ZY
    J Indian Med Assoc; 2009 Nov; 107(11):759-61. PubMed ID: 20469779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple HbA1c targets and insulin analogues in type 2 diabetes: a systematic review.
    Giugliano D; Maiorino MI; Bellastella G; Chiodini P; Esposito K
    J Diabetes Complications; 2011; 25(4):275-81. PubMed ID: 21601479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world data reveal unmet clinical needs in insulin treatment in Asian people with type 2 diabetes: the Joint Asia Diabetes Evaluation (JADE) Register.
    Kong APS; Lew T; Lau ESH; Lim LL; Kesavadev J; Jia W; Sheu WH; Sobrepena L; Tan ATB; Nguyen TK; Yoon KH; Wang K; Kodiappan K; Treuer T; Chan JCN;
    Diabetes Obes Metab; 2020 Apr; 22(4):669-679. PubMed ID: 31903728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perception of Diabetic Patients Regarding Basal Bolus Insulin Injections and Outcome of its Use.
    Shahid M; Sarfraz A; Shaikh S; Mahar SA; Alam M; Shahid N
    J Coll Physicians Surg Pak; 2016 Mar; 26(3):177-81. PubMed ID: 26975946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of basal and premixed insulin on glycemic control in type 2 diabetes patients based on multicenter prospective real-world data.
    Peng Y; Xu P; Shi J; Zhang Y; Wang S; Zheng Q; Wang Y; Ke T; Li L; Zhao D; Dai Y; Dong Q; Ji B; Xu F; Gu W; Wang W
    J Diabetes; 2022 Feb; 14(2):134-143. PubMed ID: 35023626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associated factors that influenced persistence with basal analog insulin therapy among people with type 2 diabetes: An exploratory analysis from a UK real-world sample.
    Idris I; Gulati K; Perez-Nieves M; Hadjiyianni I; Cao D; Tahbaz A; Ivanova J; Hassan SW
    Prim Care Diabetes; 2019 Apr; 13(2):106-112. PubMed ID: 30477969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of responders to insulin therapy at 1 year among adults with type 2 diabetes.
    Owen V; Seetho I; Idris I
    Diabetes Obes Metab; 2010 Oct; 12(10):865-70. PubMed ID: 20920038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin analogs and glycosylated hemoglobin target of less than 7% in type 2 diabetes: a systematic review of randomized trials.
    Esposito K; Maiorino MI; Bellastella G; Chiodini P; Giugliano D
    Metab Syndr Relat Disord; 2011 Jun; 9(3):167-76. PubMed ID: 21410335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review.
    Sheu WH; Ji L; Lee WJ; Jabbar A; Han JH; Lew T
    J Diabetes Investig; 2017 Jul; 8(4):518-534. PubMed ID: 27930869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials.
    Giugliano D; Maiorino M; Bellastella G; Chiodini P; Esposito K
    Int J Clin Pract; 2011 May; 65(5):602-12. PubMed ID: 21489084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes and resource use after 24 months of insulin therapy in Turkish patients with type 2 diabetes: subgroup analysis of the TREAT study.
    Oguz A; Cevizci E; Ertekin A; Abdulnabi R;
    Int J Clin Pract; 2015 May; 69(5):588-96. PubMed ID: 25472768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy.
    Watada H; Ross Agner BF; Doshi A; Bardtrum L; Ranthe MF; Billings LK
    Diabetes Ther; 2020 Jan; 11(1):331-339. PubMed ID: 31760599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.